ER Stress and UPR Modulator Therapy for Neurodegeneration

📖 Wiki Page

therapeutic1403 wordssynced 2026-04-02

ER Stress and UPR Modulator Therapy for Neurodegeneration

Overview

...

ER Stress and UPR Modulator Therapy for Neurodegeneration

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ER Stress and UPR Modulator Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Study</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">CENTAUR trial</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">NCT03963219</td>
<td>AD</td>
</tr>
<tr>
<td class="label">NCT02906579</td>
<td>HD</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">MTX-001</td>
<td>Mitsubishi Tanabe</td>
</tr>
<tr>
<td class="label">BIIB110</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">CC-90009</td>
<td>Bristol Myers Squibb</td>
</tr>
<tr>
<td class="label">QRL-101</td>
<td>QurAlis</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">GSK2606414</td>
<td>GSK</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>Various</td>
</tr>
<tr>
<td class="label">BIIB094</td>
<td>Biogen</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">A-966084</td>
<td>[Araim Pharmaceuticals](/companies/arim-pharmaceuticals)</td>
</tr>
<tr>
<td class="label">PF-06447656</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">REGN-9000</td>
<td>[Regeneron](/companies/regeneron)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Trap-Lect</td>
<td>[Cyclo Therapeutics](/companies/cyclo-therapeutics)</td>
</tr>
<tr>
<td class="label">YTX-7739</td>
<td>[Yumanity Therapeutics](/companies/yumanity-therapeutics)</td>
</tr>
<tr>
<td class="label">EVT-001</td>
<td>Evotec</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Evidence Strength</td>
</tr>
<tr>
<td class="label">TUDCA/PBA (Relyvrio)</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">ATF6 Activators</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">IRE1 Modulators</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">PERK Inhibitors</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">ISRIB</td>
<td>Moderate</td>
</tr>
</table>

Endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR) represent a common pathological mechanism across neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and the 4R-tauopathies (corticobasal degeneration, progressive supranuclear palsy). The UPR is a sophisticated cellular signaling network that detects misfolded proteins in the ER lumen and coordinates adaptive responses—including translational attenuation, chaperone upregulation, and ER-associated degradation (ERAD)—or triggers [apoptosis](/entities/apoptosis) if homeostasis cannot be restored. [@hetz2023]

ER stress modulator therapy aims to:

Reduce ER stress through chemical chaperones that enhance protein folding capacity

Modulate UPR signaling to favor adaptive (pro-survival) over pro-apoptotic pathways

Restore ER calcium homeostasis which is frequently dysregulated in neurodegeneration

Biological Rationale

ER Stress in Neurodegeneration

The endoplasmic reticulum is responsible for protein folding, lipid synthesis, and calcium storage. Multiple mechanisms contribute to ER stress in neurodegenerative diseases: [@gerakis2022]

[Amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology in AD impair ER calcium homeostasis
[Alpha-synuclein](/proteins/alpha-synuclein) accumulation in PD triggers ER stress through calcium dysregulation
[TDP-43](/proteins/tdp-43-protein) pathology in ALS causes ER homeostasis disruption
Mutant [huntingtin](/proteins/huntingtin) creates proteostatic overload

The Three UPR Branches

The UPR is mediated by three ER transmembrane sensors: [@Moreno2019]

IRE1 (Inositol-Requiring Enzyme 1): Autophosphorylates and splices XBP1 mRNA to produce XBP1s, driving chaperone expression. Sustained activation triggers RIDD (Regulated IRE1-Dependent Decay), which can promote apoptosis.

PERK (PKR-like ER Kinase): Phosphorylates eIF2α, attenuating global translation while selectively enhancing ATF4 translation. Chronic PERK activation leads to synaptic dysfunction and neuronal death.

ATF6 (Activating Transcription Factor 6): Translocates to the Golgi where it's cleaved to produce ATF6f, driving expression of ER chaperones and ERAD components. Considered primarily adaptive.

Therapeutic Approaches

Chemical Chaperones

Chemical chaperones are small molecules that enhance ER protein folding capacity and reduce ER stress. [@ozcan2006]

Tauroursodeoxycholic Acid (TUDCA)

TUDCA is a hydrophilic bile acid with demonstrated anti-apoptotic and ER stress-reducing properties:

Mechanism: Reduces CHOP expression, stabilizes mitochondrial membrane potential, inhibits caspase activation
Evidence in AD: Reduces ER stress markers in APP/PS1 transgenic mice, improves cognitive function
Evidence in PD: Protects dopaminergic neurons in MPTP and 6-OHDA models
Evidence in ALS: Approved as Relyvrio (sodium phenylbutyrate/taurursodiol) for ALS based on CENTAUR trial
Clinical Status: FDA-approved for ALS; investigated in AD, PD, and HD

See [TUDCA and UDCA Bile Acid Therapy](/therapeutics/tudca-udca-neurodegeneration) for detailed information.

Sodium Phenylbutyrate (PBA)

PBA is a chemical chaperone that enhances protein folding and reduces ER stress:

Mechanism: Acts as a chemical chaperone, reduces misfolded protein aggregation, upregulates ER chaperones
Evidence: FDA-approved for urea cycle disorders; shown to reduce ER stress in multiple neurodegenerative models
Combination: Combined with TUDCA in Relyvrio for ALS

IRE1 Modulators

IRE1 has dual functions—kinase and RNase activity. Modulating IRE1 can enhance adaptive XBP1s signaling while blocking pro-apoptotic RIDD. [@gerakis2022]

Therapeutic Challenge: IRE1 modulators must enhance adaptive XBP1s signaling while avoiding pro-apoptotic RIDD. Selective RNase inhibition represents a key differentiation opportunity.

PERK Inhibitors

PERK inhibitors attenuate eIF2α phosphorylation, reducing translational burden. However, they must balance pathway inhibition with blocking adaptive ATF4-driven transcription. [@Moreno2019]

ISRIB (Integrated Stress Response Inhibitor)

ISRIB enhances eIF2α activity by promoting the guanine nucleotide exchange activity of eIF2B, effectively reversing translational attenuation: [@boyce2005]

Mechanism: Binds and activates eIF2B, reversing eIF2α phosphorylation effects
Evidence: Improves cognitive function in AD mouse models, protects against neurodegeneration
Challenge: Blood-brain barrier penetration and chronic dosing

See [ISRIB Therapy](/therapeutics/isrib-therapy) and [ISR Modulator Therapy](/therapeutics/isr-modulator-therapy-neurodegeneration) for detailed information.

ATF6 Activators

ATF6 activation is considered primarily adaptive, driving expression of ER chaperones and ERAD components. [@chen2023]

BiP/Chaperone Modulators

BiP (HSPA5/GRP78) is the master ER chaperone governing protein folding and UPR sensor activation:

Clinical Evidence by Disease

Alzheimer's Disease

ER stress is an early event in AD pathogenesis:

Evidence: CHOP expression, eIF2α phosphorylation, XBP1 splicing, and GRP78/BiP levels are elevated in AD brain
Therapeutic approach: ATF6 activators, PERK inhibitors, chemical chaperones
Key trials: NCT03963219 (TUDCA in AD), multiple Phase 1 programs for IRE1/PERK modulators

Parkinson's Disease

ER stress is prominent in PD dopaminergic neurons:

Evidence: CHOP upregulation in substantia nigra, XBP1 splicing, GRP78 induction
Key genes: SNCA, LRRK2, GBA1 mutations exacerbate ER stress
Therapeutic approach: IRE1 modulators, BiP inducers, chemical chaperones
Key trials: Phase 1 completed for YTX-7739 (discontinued)

ALS

ER stress is a major contributor to motor neuron degeneration: [@paganoni2020]

Evidence: CHOP upregulation, eIF2α phosphorylation, XBP1 splicing, ATF4 activation
Key genes: SOD1, TARDBP (TDP-43), FUS, C9orf72
Therapeutic approach: IRE1 modulators, PERK inhibitors, chemical chaperones (approved)
Key trials: CENTAUR trial led to Relyvrio FDA approval

Huntington's Disease

CAG repeat expansions create inherent proteostatic stress:

Evidence: Activation of all three UPR branches
Therapeutic approach: Chemical chaperones, ATF6 activators
Key trials: NCT02906579 (TUDCA in HD)

4R-Tauopathies (CBS/PSP)

ER stress is implicated in tau pathology:

Evidence: CHOP and XBP1 splicing elevated in PSP brain tissue
Therapeutic approach: Chemical chaperones, PERK inhibitors

See [ER Stress in CBD](/mechanisms/cbd-er-stress-upr) and [ER Stress in PSP](/mechanisms/psp-endoplasmic-reticulum-stress-upr) for disease-specific mechanisms.

Therapeutic Rankings

Combination Approaches

Emerging strategies combine ER stress modulation with other therapeutic modalities:

ER stress + autophagy: TUDCA combined with [autophagy enhancers](/therapeutics/autophagy-enhancers-pd)
ER stress + mitochondria: Targeting ER-mitochondria contact sites
ER stress + neuroinflammation: Modulating UPR-inflammasome crosstalk
ER stress + proteostasis: Combined with [proteasome](/mechanisms/ubiquitin-proteasome-system) enhancement

Biomarkers for Target Engagement

Key biomarkers for ER stress/UPR modulator development:

XBP1 splicing: Readout of IRE1 RNase activity
CHOP expression: Marker of pro-apoptotic UPR activation
eIF2α phosphorylation: Readout of PERK pathway activity
ATF6 cleavage: Marker of ATF6 pathway activation
GRP78/BiP levels: General ER stress marker

Cross-Links

[ER Stress and UPR in Neurodegeneration](/mechanisms/er-stress-upr-neurodegeneration) — Primary mechanism page
[Investment Landscape: ER Stress & UPR Therapeutics](/investment/er-stress-upr-therapeutics) — Pipeline and investment analysis
[TUDCA and UDCA Bile Acid Therapy](/therapeutics/tudca-udca-neurodegeneration) — Detailed TUDCA page
[ISRIB Therapy](/therapeutics/isrib-therapy) — ISRPG detailed information
[Proteostasis Therapeutics](/therapeutics/proteostasis-therapy) — Broader proteostasis context

References

[Hetz et al., The unfolded protein response in neurodegenerative disease: A pathway-focused analysis (2023)](https://doi.org/10.1038/s41582-023-00778-4)

[Gerakis et al., IRE1 signaling in neurodegeneration: Molecular mechanisms and therapeutic opportunities (2022)](https://doi.org/10.1038/s41582-022-00663-5)

[Moreno et al., PERK inhibition as a therapeutic strategy in neurodegenerative disease (2019)](https://doi.org/10.1016/j.neuropharm.2022.109234)

[Chen et al., ATF6 as a therapeutic target for Alzheimer's disease (2023)](https://doi.org/10.1038/s41598-023-28765-5)

[Paganoni et al., Trial of sodium phenylbutyrate-taurursodiol for ALS (2020)](https://pubmed.ncbi.nlm.nih.gov/32897034/)

[Ozcan et al., Chemical chaperones reduce ER stress (2006)](https://pubmed.ncbi.nlm.nih.gov/16931762/)

[Boyce et al., A selective inhibitor of eIF2alpha dephosphorylation (2005)](https://doi.org/10.1038/nchembio0305-34)

Pathway Diagram

Mermaid diagram (expand to render)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) 🔄
[Mitochondrial transfer between astrocytes and neurons](/analysis/SDA-2026-04-01-gap-v2-89432b95) 🔄
[Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v3-20260402063622) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving ER Stress and UPR Modulator Therapy for Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

ER Stress and UPR Modulator Therapy for Neurodegeneration

ER Stress and UPR Modulator Therapy for Neurodegeneration

Overview

ER Stress and UPR Modulator Therapy for Neurodegeneration

Overview

Biological Rationale

ER Stress in Neurodegeneration

The Three UPR Branches

Therapeutic Approaches

Chemical Chaperones

Tauroursodeoxycholic Acid (TUDCA)

Sodium Phenylbutyrate (PBA)

IRE1 Modulators

PERK Inhibitors

ISRIB (Integrated Stress Response Inhibitor)

ATF6 Activators

BiP/Chaperone Modulators

Clinical Evidence by Disease

Alzheimer's Disease

Parkinson's Disease

ALS

Huntington's Disease

4R-Tauopathies (CBS/PSP)

Therapeutic Rankings

Combination Approaches

Biomarkers for Target Engagement

Cross-Links

References

Pathway Diagram

Related Hypotheses

Pathway Diagram